Remdesivir for COVID-19: The NIAID Study Behind its Approval | GameChangers

CEimpact Podcast

English - June 12, 2020 08:01 - 23 minutes - 15.8 MB
Courses Education Science ceimpact podcast precept2practice level up gamechangers pharmacy cme cpe pharmacology ceimpact geoff wall Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Treating the other Epidemic: Buprenorphine for Opioid Use Disorder | GameChangers

Next Episode: Vitamin D: Repletion doses and the evidence of potential toxicity | GameChangers

Recently, Remdesivir was given Emergency Use Authorization (EUA) status by the U.S. Food and Drug Administration (FDA) for use in COVID based on a heretofore unpublished study. The study, conducted by NIAID, is the subject of this episode.This episode is accredited for CPE. For CE details and to claim credit click here: https://bit.ly/3hn191p See omnystudio.com/listener for privacy information.

Follow CEimpact on Social Media:
LinkedIn
Instagram